Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant amivantamab with lazertinib or chemotherapy in resectable EGFR-mutated non-small cell lung cancer
2025-524816-13-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of amivantamab and lazertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Major pathological response. Planned start Jul 2026; status: authorised.
02
Drugs
amivantamablazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-524816-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524816-13-00.